



CIN: L24230GJ1972PLC002126

Website: www.torrentpharma.com

Email: investorservices@torrentpharma.com

**TORRENT PHARMACEUTICALS LIMITED**

Registered Office:

Torrent House, Off Ashram Road,  
Ahmedabad - 380 009, Gujarat, India.

Ph. : + 91 79 26599000

Fax : + 91 79 26582100

**Extract of Consolidated Financial Results  
for the Quarter and Year ended March 31, 2024**

[₹ in crores except per share data]

Particulars	Quarter Ended March 31, 2024	Year Ended March 31, 2024	Quarter Ended March 31, 2023
	Audited (Refer Note 2)	Audited	Audited (Refer Note 2)
Total Income from operations (net)	2745	10728	2491
Net Profit / (Loss) for the period before tax and exceptional items	631	2264	433
Net Profit / (Loss) for the period before tax and after exceptional items	631	2352	433
Net Profit / (Loss) for the period after tax and exceptional items	449	1656	287
Total Comprehensive Income (after tax)	450	1673	330
Equity Share Capital	169.23	169.23	169.23
Other Equity excluding Revaluation Reserve*		6687	
Earnings per share: (Face Value of ₹ 5 each)			
Basic	13.27	48.94	8.48
Diluted	13.27	48.94	8.48

\* Other Equity excluding Revaluation Reserve as on March 31, 2023 was ₹ 6029 crores.

**Notes :**

1 Summary details of standalone audited financial results of Torrent Pharmaceuticals Limited :

[₹ in crores]

Particulars	Quarter Ended March 31, 2024	Year Ended March 31, 2024	Quarter Ended March 31, 2023
Net income from operations	2143	8533	1920
Profit before tax	530	1917	328
Profit after tax	410	1357	219
Total Comprehensive Income (after tax)	424	1388	240

2 Figures for the quarter ended March 31, 2024 and March 31, 2023 represents the difference between the audited figures in respect to the full financial year and the published figures of nine months ended December 31, 2023 and December 31, 2022 (as restated as per note 3) respectively, which were subjected to limited review.

3 The Company acquired 100% shares in Curatio Health Care (I) Private Limited ('Curatio'), including its two subsidiaries, on October 14, 2022, for a total consideration of ₹ 2,000 crores. The Board of Directors of the Company, at its meeting held on December 21, 2022, approved the Scheme of Arrangement in the nature of Amalgamation ('Scheme') of Curatio with the Company subject to requisite statutory and regulatory approvals. The scheme was filed and approved by the National Company Law Tribunal ('NCLT'), Ahmedabad Bench on May 17, 2023. The management determined this as a subsequent adjusting event for previous year and hence, the financial results for the year ended March 31, 2023 reflected the financial information of Curatio from the date of its acquisition. The figures for nine months ended December 31, 2022 were restated to give effect of amalgamation.

4 The Board of Directors in their meeting held on May 24, 2024, proposed a final equity dividend of ₹ 6 per equity share.

5 The above is an extract of the detailed format of Financial Results for the quarter and year ended March 31, 2024 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on [www.nscindia.com](http://www.nscindia.com), [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.torrentpharma.com](http://www.torrentpharma.com).

Place : Mumbai, Maharashtra

Date : May 24, 2024



CIN: L24230GJ1972PLC002126

Website: www.torrentpharma.com

Email: investorservices@torrentpharma.com

**TORRENT PHARMACEUTICALS LIMITED**

Registered Office:

Torrent House, Off Ashram Road,  
Ahmedabad - 380 009, Gujarat, India.

Ph. : + 91 79 26599000

Fax : + 91 79 26582100

**Extract of Consolidated Financial Results  
for the Quarter and Year ended March 31, 2024**

[₹ in crores except per share data]

Particulars	Quarter Ended March 31, 2024	Year Ended March 31, 2024	Quarter Ended March 31, 2023
	Audited (Refer Note 2)	Audited	Audited (Refer Note 2)
Total Income from operations (net)	2745	10728	2491
Net Profit / (Loss) for the period before tax and exceptional items	631	2264	433
Net Profit / (Loss) for the period before tax and after exceptional items	631	2352	433
Net Profit / (Loss) for the period after tax and exceptional items	449	1656	287
Total Comprehensive Income (after tax)	450	1673	330
Equity Share Capital	169.23	169.23	169.23
Other Equity excluding Revaluation Reserve*		6687	
Earnings per share: (Face Value of ₹ 5 each)			
Basic	13.27	48.94	8.48
Diluted	13.27	48.94	8.48

\* Other Equity excluding Revaluation Reserve as on March 31, 2023 was ₹ 6029 crores.

**Notes :**

1 Summary details of standalone audited financial results of Torrent Pharmaceuticals Limited :

[₹ in crores]

Particulars	Quarter Ended March 31, 2024	Year Ended March 31, 2024	Quarter Ended March 31, 2023
Net income from operations	2143	8533	1920
Profit before tax	530	1917	328
Profit after tax	410	1357	219
Total Comprehensive Income (after tax)	424	1388	240

2 Figures for the quarter ended March 31, 2024 and March 31, 2023 represents the difference between the audited figures in respect to the full financial year and the published figures of nine months ended December 31, 2023 and December 31, 2022 (as restated as per note 3) respectively, which were subjected to limited review.

3 The Company acquired 100% shares in Curatio Health Care (I) Private Limited ('Curatio'), including its two subsidiaries, on October 14, 2022, for a total consideration of ₹ 2,000 crores. The Board of Directors of the Company, at its meeting held on December 21, 2022, approved the Scheme of Arrangement in the nature of Amalgamation ('Scheme') of Curatio with the Company subject to requisite statutory and regulatory approvals. The scheme was filed and approved by the National Company Law Tribunal ('NCLT'), Ahmedabad Bench on May 17, 2023. The management determined this as a subsequent adjusting event for previous year and hence, the financial results for the year ended March 31, 2023 reflected the financial information of Curatio from the date of its acquisition. The figures for nine months ended December 31, 2022 were restated to give effect of amalgamation.

4 The Board of Directors in their meeting held on May 24, 2024, proposed a final equity dividend of ₹ 6 per equity share.

5 The above is an extract of the detailed format of Financial Results for the quarter and year ended March 31, 2024 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.torrentpharma.com](http://www.torrentpharma.com).

Place : Mumbai, Maharashtra

Date : May 24, 2024